HazMat Fee +
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Structure of Doxercalciferol
CAS No.: 54573-75-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Doxercalciferol is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.
Synonyms: 1.alpha.-Hydroxyvitamin D2; 1-hydroxy Vitamin D2; Doxercalciferol. 1-hydroxy Vitamin D2
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 54573-75-0 |
| Formula : | C28H44O2 |
| M.W : | 412.65 |
| SMILES Code : | C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](/C=C/[C@@H](C(C)C)C)C)CCC/2)[H])O)O |
| Synonyms : |
1.alpha.-Hydroxyvitamin D2; 1-hydroxy Vitamin D2; Doxercalciferol. 1-hydroxy Vitamin D2
|
| MDL No. : | MFCD00871065 |
| GHS Pictogram: |
|
| Signal Word: | Danger |
| Hazard Statements: | H300 |
| Precautionary Statements: | P264-P301+P310 |
| Class: | 6.1 |
| UN#: | 2811 |
| Packing Group: | Ⅲ |
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| Huh7 cells | 1.98 ± 1.30 μmol/L (EC50) | 6 days | To evaluate the inhibitory effect of Doxercalciferol on SFTSV-induced cytopathic effect (CPE), results showed dose-dependent protection against CPE. | Virol Sin. 2024 Oct;39(5):802-811. |
| N2a wt cells | 100 nM | 18 hours | Doxercalciferol significantly increased Aβ degradation to 158.2%. | Int J Mol Sci. 2017 Dec 19;18(12):2764. |
| SH-SY5Y wt cells | 100 nM | 24 hours | Doxercalciferol significantly reduced β-secretase activity to 77.3%. | Int J Mol Sci. 2017 Dec 19;18(12):2764. |
| SH-SY5Y APP695 overexpressing cells | 100 nM | 24 hours | Doxercalciferol significantly reduced total Aβ level to 70.9%. | Int J Mol Sci. 2017 Dec 19;18(12):2764. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| ICR suckling mice | Lethal SFTSV infection model | Intraperitoneal injection | 0.3 or 0.15 μg/kg | Daily for 8 days | To evaluate the therapeutic effect of Doxercalciferol on SFTSV-infected ICR suckling mice, results showed increased survival rates (40% protection). | Virol Sin. 2024 Oct;39(5):802-811. |
| LHβ-Tag transgenic mice | Transgenic retinoblastoma model | Oral gavage | 0.1, 0.3, 0.5, or 1.0 µg/day | Five times per week for 5 weeks | To determine the effectiveness of 1α-OH-D2 in inhibiting retinoblastoma and evaluate its toxicity. Results showed significantly smaller tumor areas in all treatment groups compared to controls (P <.02), but no dose-dependent response curve. Higher mortality was observed in the 0.5 and 1.0 μg groups (P <.01). | Trans Am Ophthalmol Soc. 2002;100:125-9 |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT01717989 | - | Completed | - | - | |
| NCT01717989 | - | Completed | - | - | |
| NCT01181531 | - | Completed | - | - | |
| NCT01181531 | Hyperparathyroidism, Secondary | Phase 4 | Completed | - | - |
| NCT00135304 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | - |
| NCT00977080 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Hemodialysis Less << | Phase 4 | Completed | - | - |
| NCT00977080 | - | Completed | - | - | |
| NCT02282813 | Chronic Kidney Disease ... More >> Hyperparathyroidism, Secondary Vitamin D Deficiency Less << | Phase 3 | Completed | - | - |
| NCT01799317 | Bone Mineralization Defect | Phase 4 | Unknown | June 2014 | United States, California ... More >> Loma Linda University Recruiting Loma Linda, California, United States, 92354 Contact: Shobbha Sahney, MD 909-558-8242 ssahney@llu.edu Principal Investigator: Shobha Sahney, MD Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Kevin Lemley, MD 323-361-2295 klemley@chla.usc.edu Principal Investigator: Kevin Lemley, MD Less << |
| NCT02282813 | - | Completed | - | - | |
| NCT01100723 | - | Completed | - | - | |
| NCT01100723 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 4 | Completed | - | United States, Virginia ... More >> Lynchburg Nephrology Associates, P.L.L.C. Lynchburg, Virginia, United States, 24501 Less << |
| NCT00560300 | Secondary Hyperparathyroidism ... More >> Renal Osteodystrophy Less << | Phase 2 | Completed | - | - |
| NCT00749736 | Chronic Kidney Disease | Phase 4 | Completed | - | United States, Indiana ... More >> Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 Less << |
| NCT00257920 | Chronic Kidney Disease, Stage ... More >>5 Secondary Hyperparathyroidism Less << | Phase 4 | Completed | - | United States, Nebraska ... More >> Bellevue, Nebraska, United States, 68123 Omaha, Nebraska, United States, 68131 Less << |
| NCT00257920 | - | Completed | - | - | |
| NCT00454350 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | United States, Minnesota ... More >> Minneapolis, Minnesota, United States Less << |
| NCT00502268 | Coronary Calcification ... More >> Endstage Renal Disease Parathyroid Hormone Less << | Phase 4 | Withdrawn(study never initiate... More >>d) Less << | - | United States, North Carolina ... More >> Davita East Charlotte Dialysis Unit Charlotte, North Carolina, United States, 28208 Less << |
| NCT00463021 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | United States, California ... More >> Downey, California, United States Paramount, California, United States United States, Florida Hudson, Florida, United States United States, Georgia Augusta, Georgia, United States Decatur, Georgia, United States United States, Pennsylvania Pittsburgh, Pennsylvania, United States United States, Tennessee Nashville, Tennessee, United States United States, Virginia Norfolk, Virginia, United States Less << |
| NCT00123461 | Secondary Hyperparathyroidism ... More >> Renal Failure Chronic Renal Insufficiency Less << | Phase 4 | Completed | - | United States, Arizona ... More >> AKDHC Medical Research Services Phoenix, Arizona, United States, 85012 United States, California UCLA Diabetes Reseach Center Alhambra, California, United States Apex Research of Riverside Riverside, California, United States, 92501 United States, District of Columbia George Washington University Hospital Washington, District of Columbia, United States, 20037 United States, Florida Discovery Medical Research Group Ocala, Florida, United States, 34471 Nephrology Associates Palm Beach Gardens, Florida, United States, 33410 United States, Georgia Georgia Kidney Associates, Inc. Marietta, Georgia, United States, 30060 United States, Michigan Michigan Kidney Consultants, P.C. Pontiac, Michigan, United States, 48341 United States, Minnesota Twin Cities Clinical Research Brooklyn Center, Minnesota, United States, 55430 United States, New York Montefiore Medical Center Bronx, New York, United States University of Rochester Medical Center Rochester, New York, United States, 14642 United States, North Carolina Wake Nephrology Associates, PA Raleigh, North Carolina, United States Wake Forest University School of Medicine Winston-Salem, North Carolina, United States United States, North Dakota Altru Health System Research Center Grand Forks, North Dakota, United States, 58201 United States, Pennsylvania DaVita Lewiston Dialysis Center Lewiston, Pennsylvania, United States, 17044 Temple University Philadelphia, Pennsylvania, United States United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States Puerto Rico Instituto Renal del Este Caguas, Puerto Rico, 00725 Jose Cangiano, MD San Juan, Puerto Rico, 00918 Less << |
| NCT00646282 | Hyperparathyroidism, Secondary | Phase 4 | Terminated(slow enrollment and... More >> discontinued once original principal investigator left Emory) Less << | - | United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 Less << |
| NCT00528788 | - | Completed | - | - | |
| NCT00528788 | Hyperparathyroidism, Secondary... More >> Kidney Failure, Chronic Less << | Phase 4 | Completed | - | United States, North Carolina ... More >> Duke University Medical Center Dialysis Unit Durham, North Carolina, United States, 27705 Less << |
| NCT00022412 | Prostate Cancer | Phase 2 | Completed | - | United States, Iowa ... More >> Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa, United States, 52242-1002 United States, New York James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States, 14642 United States, Wisconsin Veterans Affairs Medical Center - Madison Madison, Wisconsin, United States, 53705 Meriter Hospital Madison, Wisconsin, United States, 53715 University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-6164 Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin, United States, 53226-3596 Less << |
| NCT00052832 | Leukemia Myel... More >>odysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Less << | Phase 2 | Completed | - | United States, Wisconsin ... More >> University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Less << |
| NCT00285467 | Renal Osteodystrophy | Not Applicable | Completed | - | United States, Indiana ... More >> Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 Less << |
| NCT00582582 | Prostate Cancer | Phase 2 | Terminated(Lack of drug supply... More >> for doxercalciferol for this study) Less << | - | United States, Wisconsin ... More >> University of Wisconsin Madison, Wisconsin, United States, 53792-5669 Less << |
| NCT00511017 | Solid Tumors | PHASE1 | TERMINATED | 2025-09-10 | UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less << |
| NCT00646282 | - | Terminated(slow enrollment and... More >> discontinued once original principal investigator left Emory) Less << | - | - | |
| NCT00285467 | - | Completed | - | - | |
| NCT00601107 | Moderate to Severe Chronic Pla... More >>que Psoriasis Less << | Phase 2 | Completed | - | - |
| NCT00889629 | Chronic Kidney Disease ... More >> Kidney Transplantation Less << | Phase 4 | Unknown | January 2010 | United States, New York ... More >> SUNY Downstate Medical Center Recruiting Brooklyn, New York, United States, 11234 Contact: Sima Terebelo, MPH, RPA-C 718-270-8216 Principal Investigator: Mariana Markell, MD Sub-Investigator: Sima Terebelo, MPH, RPA-C Less << |
| NCT00418600 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | United States, Arkansas ... More >> Hot Springs, Arkansas, United States United States, California Downey, California, United States Tarzana, California, United States United States, Georgia Atlanta, Georgia, United States United States, Ohio Cincinnati, Ohio, United States United States, Pennsylvania Pittsburgh, Pennsylvania, United States United States, Texas Houston, Texas, United States United States, Washington Spokane, Washington, United States Less << |
| NCT00601107 | - | Completed | - | - | |
| NCT00792857 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Chronic Renal Insufficiency Chronic Renal Failure Less << | Phase 1 | Completed | - | United States, Arizona ... More >> Pivotal Reseach Centers Peoria, Arizona, United States, 85381 United States, Massachusetts Western New England Renal and Transplant Associates Springfield, Massachusetts, United States, 01107 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45206 United States, Pennsylvania Northeast Clinical Research Allentown, Pennsylvania, United States, 18103-6379 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Texas Southwest Houston Research Ltd. Houston, Texas, United States, 77099 Less << |
| NCT02859896 | Secondary Hyperparathyroidism-... More >>Chronic Kidney Disease Less << | Phase 3 | Recruiting | April 2, 2020 | - |
Tags: Doxercalciferol | 1.alpha.-Hydroxyvitamin D2 | VD/VDR | Vitamin D | Vitamin D receptor | VD/VDR activator | vitamin D2 analog | vitamin D receptor | calcium balance | parathyroid hormone regulation | 54573-75-0
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


